According to the National Cancer Institute a biomarker is “a biological molecule found in blood, other body fluids or tissues that is a sign of a normal or abnormal process or of a condition or disease” (NCI) such as cancer.
Biomarkers typically differentiate an affected patient from a person without the disease. There is tremendous variety of biomarkers which can include:
A biomarker can also be a collection of alterations such as gene expression, proteomic, and metabolomic signatures.
Biomarkers can be detected in the circulation (whole blood, serum, or plasma) or excretions or secretions (stool, urine, sputum, or nipple discharge) and thus easily assessed non-invasively and serially. Biomarkers can also be tissue-derived and require either biopsy or special imaging for evaluation.
Sign up to learn about new research and developments from BioMark
Biomarkers have many potential applications in oncology including:
19
Aug, 2019
Vancouver, British Columbia – (August 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot…
READ MORE
31
May, 2019
MAY 31, 2019 — Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and is characterized by its infiltrative and often fatal progression. The strikingly poor survival for patients with GBM of 14-16 months following diagnosis is due in part to limited early detection methods and an absence of effective treatment options. Funding from the Canadian Institute of Health Research of $753,432 was awarded to professor Donald Miller…
READ MORENovember 21, 2019
Vancouver, British Columbia – (November 21st, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce a non-brokered Private Placement (the “Offering”). The Offering will be for up to 1,666,667 Units at a price of $0.30 to raise gross proceeds of up to $500,000. Each Unit is composed of one common share (a “Share”) of the Company and one-half Share purchase warrant (a “Warrant”). Each whole Warrant shall entitle the holder to acquire one Share at a price of $0.45 per Share for […]
BioMark has been over the years, funded by various government agencies and Foundation including NRC IRAP, NRC Engage, Genome BC, Government of Manitoba and DFAIT Canada for various projects with active collaboration at University of British Columbia, University of Manitoba, University of Victoria, University of Waterloo, and University of Alberta. Now BioMark is collaborating with Bio banks across Canada and United States to expand our metabolomics study.